(Rac) -Ruxolitinib-d9

(Rac) -Ruxolitinib D9 ((Rac) -INCB18424 D9) is the deuterium labeled (Rac) -Ruxolitinib. (Rac) -Ruxolitinib is a JAK2 inhibitor[1].

Product Specifications

CAS Number

[2469553-67-9]

Product Name Alternative

(Rac) -INCB18424-d9; Ruxotinib racemate-d9

UNSPSC

12352005

Target

Isotope-Labeled Compounds; JAK

Type

Isotope-Labeled Compounds

Related Pathways

Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.44

Solubility

10 mM in DMSO

Smiles

N#CCC(C1([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])N2C=C(C=N2)C3=C4C(NC=C4)=NC=N3

Molecular Formula

C17H9D9N6

Molecular Weight

315.42

References & Citations

[1]Yaoyu CHEN, et al. Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. Patent WO2021102258A1|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.